Kizzmekia Corbett

Kizzmekia Corbett is an American immunologist and viral immunologist known for her leadership in the design and development of an mRNA vaccine against SARS‑CoV‑2. She worked at the Vaccine Research Center of the National Institutes of Health and collaborated with Moderna, Pfizer, and academic partners to translate basic science into clinical candidates during the COVID‑19 pandemic. Corbett's career spans translational research, science communication, and public health outreach involving multiple federal and academic institutions.

Early life and education

Corbett was born in Nashville, Tennessee and raised in the United States where she attended Harvard University‑affiliated programs and regional schools before matriculating at the University of Maryland, Baltimore County. At UMBC she studied chemistry and biological sciences under programs connected to Howard University, Johns Hopkins University, and summer research partnerships with the National Institute of Allergy and Infectious Diseases and National Institutes of Health. She completed doctoral studies in microbiology and immunology at the University of North Carolina at Chapel Hill in a program linked to collaborations with Duke University, Centers for Disease Control and Prevention, and faculty who had appointments at Emory University and Wake Forest University.

Research career

Corbett's early research focused on viral immunology and antigen design with mentors who trained at Rockefeller University, Scripps Research, and Cold Spring Harbor Laboratory. At the Vaccine Research Center she worked alongside investigators from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, and partnered with biotechnology firms including Moderna and academic groups at Massachusetts Institute of Technology and Harvard Medical School. Her laboratory work integrated techniques from structural biology employed at National Synchrotron Light Source, protein engineering strategies similar to those used by teams at Stanford University and California Institute of Technology, and neutralization assays common to Imperial College London and University of Oxford research groups.

Role in COVID-19 vaccine development

During the COVID‑19 pandemic, Corbett led antigen design efforts targeting the spike protein of SARS‑CoV‑2, collaborating with teams at Moderna, Pfizer, BioNTech, and clinical partners at Johns Hopkins University and Massachusetts General Hospital. Her work built on prior coronavirus research from groups at University of North Carolina at Chapel Hill, University of Texas Medical Branch, and University of Hong Kong that characterized neutralizing epitopes and conformational stabilization of viral proteins. Corbett contributed to preclinical studies that informed Phase I trials overseen by the Food and Drug Administration and regulatory science engagement with Operation Warp Speed and advisory panels involving experts from World Health Organization, Centers for Disease Control and Prevention, and academic advisors from Yale University and Columbia University.

Later career and public engagement

Following the initial vaccine rollout, Corbett moved into roles combining research, policy, and communication with institutions such as Harvard University, Massachusetts Institute of Technology, and advisory boards connected to National Institutes of Health and Biomedical Advanced Research and Development Authority. She has appeared in public forums alongside leaders from Bill & Melinda Gates Foundation, American Association for the Advancement of Science, and voices from The Lancet and Nature commentary. Corbett has participated in outreach to communities via partnerships with NAACP, Black Girls CODE, and historically black colleges and universities including Howard University and Spelman College, while engaging media outlets such as The New York Times, The Washington Post, and broadcast platforms like NPR and BBC.

Awards and honors

Corbett has received recognition from organizations including awards associated with National Institutes of Health, citations from U.S. Department of Health and Human Services, and honors presented by academic societies such as the American Association of Immunologists and Infectious Diseases Society of America. She has been profiled by publications like Time (magazine), Forbes, and Science (journal), and included in lists produced by Nature (journal), Bloomberg, and Smithsonian Institution exhibitions highlighting contributions to pandemic response.

Category:American immunologists Category:Women virologists